ResearcherZhejiang UniversityActive in the last 2 years
Fujing Ge
Matched on ORCID iD 0000-0003-2742-0200; OpenAlex author ID A5052188949. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2024: 1 paper · 2025: 1 paper
Papers 2
- IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC. Co-author DOI 10.1016/j.celrep.2025.116476↗
- Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis. Co-author DOI 10.1016/j.bbadis.2023.166852↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Qiaojun He · 2 shared papers, 2024–2025 · strength 0.42
- Paper Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis. DOI 10.1016/j.bbadis.2023.166852↗
- Paper IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in P… DOI 10.1016/j.celrep.2025.116476↗
- Bo Yang · 2 shared papers, 2024–2025 · strength 0.42
- Paper Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis. DOI 10.1016/j.bbadis.2023.166852↗
- Paper IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in P… DOI 10.1016/j.celrep.2025.116476↗
- Liu Yang · 2 shared papers, 2024–2025 · strength 0.42
- Paper Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis. DOI 10.1016/j.bbadis.2023.166852↗
- Paper IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in P… DOI 10.1016/j.celrep.2025.116476↗
- Xin Dong · 1 shared paper, 2025 · strength 0.21
- Yulian Wu · 1 shared paper, 2025 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.